Pharmaceutical Cost Transparency Act of 2015, California Legislation - AB 463 Eve Bukowski, California Life Sciences Association
|
|
- Brittney McBride
- 6 years ago
- Views:
Transcription
1
2 21 st Century Cures Overview Max Bronstein, The EveryLife Foundation Pharmaceutical Cost Transparency Act of 2015, California Legislation - AB 463 Eve Bukowski, California Life Sciences Association CCM-CARE bill - Amy Akers, Angioma Alliance State Level Rare Disease Advisory Council Patty Weltin, Rare Diseases United Foundation Patients Alliance for Drug Safety Protections and information about REMS Michael Losow RDLA Updates Andy Russell, The EveryLife Foundation
3 21 st Century Cures Update Max G. Bronstein Senior Director, Government & Public Affairs EveryLife Foundation for Rare Diseases
4 Quick History Roundtables, whitepapers, and briefings commenced in 2014 Four legislative drafts have been introduced 300+ page bill passed subcommittee markup Full committee will vote on full legislative package tomorrow Next stop, House Floor Senate: Innovation for Healthier Americans
5 Rare Disease Provisions - IN Orphan Product Extensions Now, Accelerating Cures & Treatments (OPEN ACT) NIH Funding Expanding Hope Act (Priority Review Vouchers) Neurological Disease Surveillance Compassionate Use Reform & Enhancement Act (Expanded Access) Patient Focused Drug Development Precision Medicine
6 Rare Disease Provisions - OUT Dormant Therapies Act/MODDERN Advancing Care for Exceptional Kids Act (ACE Kids) Genetically Targeted Platform Technologies for Rare Diseases
7 OPEN ACT - Orphan Product Extension Now, Accelerating Cures and Treatments HR 971 Provision creates a six-month exclusivity extension for drugs repurposed for a rare disease indication Modeled after Best Pharmaceuticals for Children Act Could double the number of rare disease treatments available to patients
8 NIH Funding Bill includes novel funding mechanism: Innovation Fund Allows $2B/year for five years in mandatory funding Authorizes significant annual increases for 3 years (funds must be appropriated)
9 Expanding Hope Act Companies that create treatments for rare pediatric diseases are awarded a priority review voucher The voucher greatly speeds up the drug approval process and is transferrable Passed in FDASIA (2012) 21 st Century Cures reauthorizes program until 2018
10 Neurological Disease Surveillance HR 292 Provision to national data collection system at the CDC Critical for monitoring prevalence and progression of neurological diseases
11 Compassionate Use Reform & Enhancement CURE Act (Expanded Access) HR 909 Provisions requiring companies to post expanded access policies online FDA is required to issue a guidance
12 Dormant Therapies Act (MODDERN) Was not included in final 21 st Century Cures Legislation Bill in current form would extend patent life for drugs to treat complex and rare diseases with unmet medical need Hopeful that bill could be introduced in the Senate
13 21st Century Cures Initiative: Priorities for the Rare Disease Community Thursday May 21, :30 pm 1:30 pm (lunch provided) Rayburn House Office Building Room: B318 Compassionate Use & Reform Enhancement Act (CURE Act), Rep. Michael McCaul (R-TX) Dormant Therapies and MODDERN Cures Act, Rep. Leonard Lance (R-NJ) Orphan Product Extensions Now, Accelerating Cures & Treatments (OPEN ACT), Rep. Gus Bilirakis (R-FL) Overview and Outlook for 21st Century Cures, Steve Usdin, Senior Editor, BioCentury Publications Patient Focused Drug Discovery, Kim McCleary, Director of Strategic Initiatives, FasterCures Advancing Hope Act/Pediatric Priority Review Voucher, Nancy Goodman, Executive Director, Kids V. Cancer Rare Disease Patient Organization Perspective, Paul Melmeyer, Assistant Director of Public Policy, NORD NIH Funding Provisions, Ellie Dehoney, Vice President of Policy & Advocacy, Research!America Moderator: Max G. Bronstein, Senior Director, Public & Government Affairs, EveryLife Foundation for Rare Diseases
14 Questions?
15 Eve Bukowski, Vice President State Government Affairs, California Life Sciences Association
16 Cerebral Cavernous Malformations Clinical Awareness, Research and Education Act of 2015 (CCM-CARE) Amy Akers, PhD Chief Scientific Officer Angioma Alliance
17 Cerebral Cavernous Malformations (CCM)
18 Cerebral Cavernous Malformations (CCM) Symptoms include: neurological deficits, seizure, stroke or sudden death Sporadic vs. familial CCM Affects adults and children Biological Mechanism beginning to be understood No drug treatment; brain surgery remains only option, but not suitable for all patients
19
20 Unmet Clinical Need Need for non-invasive therapy Increased research opportunities Infrastructure & support for clinical trials Challenge Advocates can not fund all of these initiatives No current funding mechanism
21 CCM Clinical Awareness, Research and Education Act of 2015 (CCM-CARE) Purpose To increase research, education and treatment for CCM Key Features 1. Expansion and Coordination of Activities of NIH with respect to CCM Research 2. Centers for Disease Control and Prevention CCM Surveillance and Research Programs 3. FDA CCM Clinical Trial Preparedness and Support Program
22 CCM Clinical Awareness, Research and Education Act of 2015 (CCM-CARE) Key Features 1. Expansion and Coordination of Activities of NIH with respect to CCM Research Coordinate efforts at NIH and provide grant support for research Basic, translational & clinical research Clinical trial Preparedness Clinical Centers Coordination Centers with current CCM research, expertise, infrastructure & patient population Participation Centers without current CCM research and/or expertise; part of another network (e.g.. stroke network) and will complete education program to become CCM participation center Oversight of centers by CCM Consortium composed of advocates, coordinating center leadership & government agencies 2. Centers for Disease Control and Prevention CCM Surveillance and Research Programs Grants for epidemiology research 3. FDA CCM Clinical Trial Preparedness and Support Program Coordination with clinical centers to support IND applications Support for Orphan Product development, where appropriate
23 Advocate Support Direct Support Letters of support Awareness Single Disease Legislation necessary where no other funding mechanisms exist or where there is a mismatch between NIH research networks and diseasespecific research centers
24 For more Information Amy Akers at
25 State Rare Disease Advisory Council Legislation
26 What is the purpose behind the Rare Disease Advisory Council legislation? This legislation would create a Rare Disease Advisory Council by state made up of public health officials, medical professionals, patient advocates and other sta How is the Council appointed? This council would be overseen by the Department of Public Health. The Department of Public Health shal
27 Can anyone file legislation for a Rare Disease Advisory Council? Anyone can file the legislation. You do not need to be a member of the Rare Disease United Foundation (RDUF) to file. This legislation has been filed in Rhode Island, Massachusetts, Connecticut, and New Jersey by RDUF. It also has been filed in North Carolina, where it has passed. Where can I find the legislation and can it be changed? A copy of the legislation filed in MA is on our website. A link can be found at the end of the presentation. Each state has made small changes to the language. The MA legislation is a great place to start.
28 How can I get this legislation filed and passed in my state? The process of filing legislation in each state is different, but the basic procedure is as follows: Find a state representative to file the legislation Look for co-sponsors for the legislation. Once the legislation if filed, start preparing to testify. The testimony can be given in person when the bill is heard or through submitted written testimony. Find out which committee will be hearing the legislation. If you have people who can testify in person who are constituents of a committee member, it holds more weight. Generally, oral testimony is limited to 3 minutes or so. If you can, try not reading your testimony. Committee members are more engaged when people are looking and speaking to them.
29 What are some problems I might encounter after filing? Asking for money for research, etc. makes it difficult for state legislation to pass. Although, there is some cost associated with this bill, it is important to stress that working on the issues surrounding rare diseases will eventually save the state money. It might be difficult to find others in your state who can testify. Rare Disease United Foundation has set up Rare Disease Community Facebook groups for each state. Please feel free to use these groups to organize your efforts. A link can be found at the end of the presentation. What if I decide to change something? Legislation can always be amended. Your sponsor should guide you through the process.
30 What if the legislation does not pass? It is very often the case that legislation will not pass on the first go around. Often, legislation takes a few years to pass. It is a very slow process. What can I do if the bill passes out of committee, but is opposed by the Department of Health? This has happened in some of the states where it has already been filed. In North Carolina, the coalition group was able to have the University of North Carolina take on the Council.
31 State Legislation for the Future Legislation that would have dental issues related to rare disease conditions or other illness coded as medical to insure coverage. Many rare diseases negatively affect the teeth. Costly procedures to deal with dental issues are generally not covered by insurance. Legislation to introduce rare disease education into health classes in public middle schools. Raising awareness at this level not only creates a generation of people who will already understand the issues surrounding rare, but will create tolerance of those living with a rare disease.
32 Please remember that your state and federal representatives work for you! Including caregivers, there are 80 million living rare. Together we are powerful! Rare Disease United Foundation is available to support you in your efforts!
33 Resources & Links Rare Disease United Foundation Website: Link to Massachusetts Legislation: Link to State Facebook Groups: RDUF at:
34 REMS & ETASU Patient Advocacy Concerns With Current Legislative Proposals
35 REMS Background 2007 the Food and Drug Administration Amendments Act (FDAAA) gave FDA the ability to require important patient safety protections, called Risk Evaluation and Mitigation Strategies (REMS), as a way to approve new medicines for patients with unmet medical needs that carry known safety risks Defined by FDA as a strategy to manage a known or potential serious risk associated with a drug or biological product, REMS are structured plans to manage specific risks of medicines that are effective but associated with known or potential serious risks (e.g., injury, death) that, without REMS, may outweigh benefits.
36 ETASU In situations where drugs and biologics carry specific, known serious risks, FDA may require highly stringent safety precautions as part of the REMS program. Called Elements to Assure Safe Use (ETASU), these carefully planned safety protocols are the most extensive elements of a REMS. ETASU are required rarely and only when the agency determines that due to a medicine s inherent toxicity or potential harmfulness, the medication can only be approved with stringent controls in place to ensure a serious or fatal risk can be avoided by proper use.
37 Conditions Impacted Asthma COPD Blood disorders Rare cholesterol disorder Dupuytren s Multiple myeloma Thyroid cancer Irregular heartbeat Pulmonary hypertension Hypogonadism Lipodystrophy Multiple sclerosis Seizures/rare infant spasms Schizophrenia Bi-polar disorder Crohn's disease and specific bowel disorders Other rare disorders
38 Scope of REMS and ETASU 2011 FDA authorized 222 REMS programs (Since then the agency released 145 less potentially toxic drugs from their REMS requirements) January 2015, only 71 products have authorized unique REMS programs 34 are subject to the more restrictive Elements to Assure Safe Use An estimated 25 or fewer, require restricted distribution systems Restricted distribution systems are implemented to ensure that a drug or biologic known to cause birth defects, organ damage and other serious or life-threatening events is only acquired and used by patients under carefully controlled conditions.
39 Issues The proposed legislation would: require the force sale of drugs subject to REMS requirements for BE testing to nearly anyone a basement lab scientist or legitimate generic manufacturer without distinction without any safeguards to ensure these medicines are handled and administered safely weaken these drug safety protections and absolve generic manufacturers from liability should a generic version of a medicine known to cause serious risks lead to injury, birth defects, organ failure and even death
40
41 Members of Congress will return home to their districts to connect with constituents for summer recess August 3rd September 4 th This is the perfect opportunity for rare disease advocates to strengthen relationships with Members of Congress or build new relationships if you have not been able to advocate in Washington, DC! Registration opens in June! Webinar Dates: July 15 th and August 5 th Meetings take place Aug 3rd-Sept 4th
42 RDLA is coming to you! Before In-District Lobby Days start, RDLA is organizing two regional legislative conferences aimed at helping advocates prepare for meetings with their legislators on rare disease issues. California UCSF, Mission Bay Campus: July 31 st New Jersey Rutgers: July 20 th
43 21st Century Cures Initiative: Priorities for the Rare Disease Community Thursday May 21, :30 pm 1:30 pm (lunch provided) Rayburn House Office Building Room: B318 Agenda: Dormant Therapies and MODDERN Cures Act, Rep. Leonard Lance (R-NJ) Orphan Product Extensions Now, Accelerating Cures & Treatments (OPEN ACT), Rep. Gus Bilirakis (R-FL) Compassion Use Enhancement and Reform Act, Rep. Michael McCaul (R-TX) Overview and Outlook for 21st Century Cures, Steve Usdin, Senior Editor, BioCentury Publications Patient Focused Drug Discovery, Kim McCleary, Director of Strategic Initiatives, FasterCures Advancing Hope Act/Pediatric Priority Review Voucher, Nancy Goodman, Executive Director, Kids V. Cancer Rare Disease Patient Organization Perspective, Paul Melmeyer, Assistant Director of Public Policy, NORD NIH Funding Provisions, Ellie Dehoney, Vice President of Policy & Advocacy, Research!America Briefing Sponsored by: Abbvie, Shire, Amgen, Raptor, Alexion, Genzyme, BioMarin, Vertex, Novartis, RDLA, NORD, FasterCures, Polycystic Kidney Disease (PKD) Foundation, National MPS Society, Noah's Hope, Batten Disease Support & Research Association,
44
45 Join us next month on June 17 th at 1:00 pm EST to discuss the events surrounding the Rare Disease Community Agenda is Open! Please send potential agenda items to:
Associate Director of Public Policy, National Organization for Rare Disorders (NORD)
Orphan Drug Act: Paul Melmeyer Associate Director of Public Policy, National Organization for Rare Disorders (NORD) Priority Review Vouchers: Ronald Bartek Co-Founder/Founding President, Friedreich s Ataxia
More informationRobert J. Beall, PhD, President and Chief Executive Officer Cystic Fibrosis Foundation
Name and Organization: Robert J. Beall, PhD, President and Chief Executive Officer Cystic Fibrosis Foundation Subject of Testimony: Food and Drug Administration Funding for Fiscal Year 2013 Point of Contact:
More informationMarch 2, Dear Chairman Upton, Ranking Member Pallone, and Representative DeGette:
March 2, 2015 The Honorable Fred Upton Chairman Energy and Commerce Committee House of Representatives Washington, DC 20515 The Honorable Frank Pallone Ranking Member Energy and Commerce Committee House
More informationAlliance for Regenerative Medicine
Alliance for Regenerative Medicine Michael Werner Executive Director Alliance for Regenerative Medicine ARM s Focus & Role As the leading global advocate for the regenerative medicine and advanced therapies
More information2015 Policy Landscape: A Biomedical R&D Planning Guide
2015 Policy Landscape: A Biomedical R&D Planning Guide A FasterCures Webinar Jan. 29, 2015 Action FasterCures is an action tank driven by a singular goal to save lives by speeding up and improving the
More informationOrphan Products and Drug Development 2015 MARLENE E. HAFFNER, MD MPH HAFFNER ASSOCIATES AS PRESENTED TO GLG SEPTEMBER 23RD, 2015
Orphan Products and Drug Development 2015 MARLENE E. HAFFNER, MD MPH HAFFNER ASSOCIATES AS PRESENTED TO GLG SEPTEMBER 23RD, 2015 What are Orphan's? Drug Development Rare Diseases Orphan Drug Act of 1983
More informationTHE FDA, THE DRUG APPROVAL PROCESS, AND THE PATIENT VOICE
THE FDA, THE DRUG APPROVAL PROCESS, AND THE PATIENT VOICE Ali Mohamadi, M.D. Senior Director, Global Regulatory Patient Engagement and Policy BioMarin Pharmaceutical 30-July-2016 Goals of Today s Presentation
More informationA Discussion Focused on Right to Try
Abigail Alliance for Better Access to Developmental Drugs A Discussion Focused on Right to Try CBI Expanded Access Programs 2017 March 9-10, 2017 Alexandria, VA Steven Walker Co-Founder, Abigail Alliance
More informationRare Diseases Drug Development and Patient Perspective Initiatives at FDA
Rare Diseases Drug Development and Patient Perspective Initiatives at FDA Jonathan C. Goldsmith, MD, FACP Associate Director Rare Diseases Program/OND/CDER/FDA EveryLife Foundation for Rare Diseases Annual
More informationEXPANDED ACCESS: RECENT LEGISLATION AND POLICY UPDATE
EXPANDED ACCESS: RECENT LEGISLATION AND POLICY UPDATE 21 st Century Cures and Beyond Policy and Regulatory Frameworks Shaping Early Access February 23, 2016 David J. Farber Partner King & Spalding LLP
More informationThe Evolving Regulatory Landscape for Orphan Drugs: FDA Perspectives
The Evolving Regulatory Landscape for Orphan Drugs: FDA Perspectives Debra Lewis, O.D., M.B.A. Acting Director, Office of Orphan Products Development FDLI May 4, 2018 OOPD Core Programs Mission: To promote
More informationRegulatory Market Update: What are the major changes and differences worldwide?
Regulatory Market Update: What are the major changes and differences worldwide? Marlene E. Haffner MD, MPH, CEO Haffner Associates Orphan Drug Summit 2015 Copenhagen, Denmark September 17, 2015 Orphan
More informationThe 21st Century Cures Act
The 21st Century Cures Act Published: Dec 14, 2016 By: David S. Guzick, M.D., Ph.D.Category: UF Health In recent weeks, the 21st Century Cures Act was passed overwhelmingly by both chambers of the U.S.
More informationImplementing the 21 st Century Cures Act: Supporting Orphan Drug Development
Implementing the 21 st Century Cures Act: Supporting Orphan Drug Development Rare Disease Congressional Caucus Briefing March 2, 2017 Frank Sasinowski, M.S., M.P.H., J.D. Director, Hyman, Phelps & McNamara,
More informationSummary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015
Pediatric-Specific Provisions Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015 Requires the NIH to complete a strategic plan, and in the
More informationYes, You Can Teach an Old Drug New Tricks: Regulatory Pathway for Repurposed Drugs
Yes, You Can Teach an Old Drug New Tricks: Regulatory Pathway for Repurposed Drugs 1 Kurt R. Karst Hyman, Phelps & McNamara, P.C. March 17, 2017 Agenda Drug Repurposing What is it? And why do it? Regulatory
More informationDear Chairmen Upton and Pitts, Ranking Members Pallone and Green, and Ms. DeGette:
May 29, 2015 The Honorable Fred Upton, Chairman 2125 Rayburn House Office Building The Honorable Joseph Pitts, Chairman 420 Cannon House Office Building The Honorable Frank Pallone, Ranking Member 2322A
More informationSec Short title; finding. Sec Authority to assess and use drug fees. Sec Reauthorization; reporting requirements.
H.R. 2430, FDA Reauthorization Act of 2017 Section 1. Short Title. This Act may be cited as the FDA Reauthorization Act of 2017. Section 2. Table of Contents Table of Contents TITLE I: FEES RELATING TO
More informationFederal Funding for Brain Research. Congressional Support Accelerates Discovery
The American Brain Coalition (ABC) is a non-profit organization that brings together people with disabling brain disorders, the families of those that are affected, and the professionals who research and
More informationNew Drug Application (NDA) Webinar December 6, 2016
New Drug Application (NDA) Webinar December 6, 2016 Introduction Presenter: Jill Jarecki Chief Scientific Officer, Cure SMA New Drug Application Process NDA Not yet an approved therapy: ~90% chance of
More informationMay 13, Washington, DC Washington, DC Washington, DC Washington, DC 20515
May 13, 2015 The Honorable Fred Upton The Honorable Frank Pallone Chairman Ranking Member Washington, DC 20515 Washington, DC 20515 The Honorable Joe Pitts The Honorable Gene Green Chairman, Subcommittee
More informationAnnie Kennedy, Parent Project Muscular Dystrophy (PPMD) Testimony FDA PDUFA Stakeholder Meeting White Oak ~ December 17, 2015
Annie Kennedy, Parent Project Muscular Dystrophy (PPMD) Testimony FDA PDUFA Stakeholder Meeting White Oak ~ December 17, 2015 On behalf of Parent Project Muscular Dystrophy (PPMD), we are most grateful
More informationOn behalf of the Cystic Fibrosis Foundation (CFF) and the 30,000 people with cystic
Robert J. Beall, Ph.D. President and Chief Executive Officer Cystic Fibrosis Foundation On behalf of the Cystic Fibrosis Foundation (CFF) and the 30,000 people with cystic fibrosis (CF) in the United States,
More informationWhile individually rare, orphan diseases are actually collectively common, with an OF ORPHAN DRUG DEVELOPMENT MEETING THE UNIQUE CHALLENGES
ELECTRONICALLY REPRINTED FROM JUNE 2017 CLINICAL TRIALS Rare Diseases: MEETING THE UNIQUE CHALLENGES OF ORPHAN DRUG DEVELOPMENT BY MICHAEL F. MURPHY, MD, Ph D While individually rare, orphan diseases are
More informationPatient Focused Drug Development 2.0
Patient Focused Drug Development 2.0 September 15, 2015 Pat Furlong, PPMD ParentProjectMD.org Understanding the Duchenne Muscular Dystrophy Environment 2 About Duchenne muscular dystrophy X-linked, pediatric
More informationGAO. PEDIATRIC DRUG RESEARCH The Study and Labeling of Drugs for Pediatric Use under the Best Pharmaceuticals for Children Act
GAO For Release on Delivery Expected at 10:00 a.m. EDT Tuesday, May 22, 2007 United States Government Accountability Office Testimony Before the Subcommittee on Health, Committee on Energy and Commerce,
More informationFDA from a Former FDAer: Secrets and insights into regulatory review and drug development
FDA from a Former FDAer: Secrets and insights into regulatory review and drug development Andrew E. Mulberg, MD, FAAP Vice-President, Global Regulatory Affairs; Former Division Deputy, DGIEP, U.S. FDA
More informationRegulatory Issues Affecting Commercialization Michael Werner Executive Director, Alliance for Regenerative Medicine Partner, Holland & Knight, LLP
Regulatory Issues Affecting Commercialization Michael Werner Executive Director, Alliance for Regenerative Medicine Partner, Holland & Knight, LLP Terrapin Conference, Sept. 2011 Alliance for Regenerative
More informationD. Enhancing Regulatory Science and Expediting Drug Development:
August 22, 2016 Division of Dockets Management (HFA-305) U.S. Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852 Re: Docket No. FDA-2016-N-1895-0001: Prescription Drug User Fee
More informationThe world s largest commercially-focused orphan drug event
The world s largest commercially-focused orphan drug event The Mandarin Oriental Hotel Washington D.C. USA Expo dates: 10-11 April 2013 Expo times: 10:00am-4:00pm PROMO CODE SPARE Book now for free at
More informationEducation Critical to Stem Cell Therapy Pipeline
June 2016 Education Critical to Stem Cell Therapy Pipeline Don L. Gibbons Senior Science and Education Communication Officer ABOUT California Institute for Regenerative Medicine (CIRM) CIRM is California
More informationWe've all heard the dismal statistics: 10,000 known diseases with only 500 treatments. Not great odds if you're a patient.
No longer just passengers, patients are now co-pilots helping to navigate the future of medical progress. But until recently, the pace of progress has been slow. In some diseases, we still utter the words
More informationNational Health Council
National Health Council 1730 M Street NW, Suite 500, Washington, DC 20036-4561 202-785-3910 www.nationalhealthcouncil.org info@nhcouncil.org BOARD OF DIRECTORS Chairperson Randy Beranek National Psoriasis
More informationTHE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION
THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION William S. Dalton, PhD, MD AACR April 17, 2016 Designing a Federated Model To Support Research & Healthcare Offices
More informationAgenda: Opportunities in Developing Orphan Drug Products. Mukesh Kumar, PhD, RAC
This Seminar is Brought to you by Amarex Clinical Research Washington DC metro area A Product Development Services Company From Lab to Market Approval FDA Meetings Global Regulatory Submissions Global
More informationHealth Industry Alert
Health Industry Alert August 4, 2017 Senate Passes Long-Awaited FDA User Fee Package Following nearly two years of negotiations and hearings examining the Generic Drug User Fee Amendments (GDUFA) and the
More informationCompassionate Use: Perspectives from a Patient Advocacy Group
Compassionate Use: Perspectives from a Patient Advocacy Group American Society of Clinical Oncology Annual Meeting 2016 Samantha Roberts, PhD Director of Scientific Affairs, Friends of Cancer Research
More informationVolunteering for Clinical Trials
Volunteering for Clinical Trials Volunteering for Clinical Trials When considering volunteering for a clinical trial, it is important to make an informed decision. Below are answers to frequently asked
More informationIntroduction. Summary A LOOK AT CFTR MODULATORS FOR CYSTIC FIBROSIS JUNE 2018 TREATMENT OPTIONS CYSTIC FIBROSIS POLICY IMPLICATIONS
JUNE 2018 Introduction CYSTIC FIBROSIS Cystic fibrosis (CF) is a progressive genetic disease that affects many organ systems, though a significant proportion of its morbidity and mortality is associated
More informationHUDs and HDEs: Common Misconceptions and Current Challenges. By Stephen P. Rhodes and Elisa D. Harvey, MS, PhD, DVM
HUDs and HDEs: Common Misconceptions and Current Challenges By Stephen P. Rhodes and Elisa D. Harvey, MS, PhD, DVM 20 January 2011 As former US Food and Drug Administration (FDA) employees working in the
More informationDrug Safety and FDA Revitalization Legislation
Drug Safety and FDA Revitalization Legislation Dan Kracov August 23, 2007 FDA Regulatory and Compliance Symposium House and Senate FDA Revitalization Bills Senate: S. 1082, Food and Drug Administration
More informationStem Cell Research: Identifying emerging high priority policy issues
The state stem cell agency Stem Cell Research: Identifying emerging high priority policy issues Ellen G. Feigal, M.D. SVP, Research and Development National Cancer Policy Summit Washington, DC November
More informationChairman Cole, Ranking Member DeLauro and distinguished members of the
Fiscal Year 2019 House Appropriations Committee Subcommittee on Labor, Health and Human Services, Education and Related Agencies Appropriations Testimony Cynthia A. Bens, Senior Vice President, Public
More informationRegulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ
Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives
More informationCLINICAL TRIALS AND MARKET RESEARCH
CLINICAL TRIALS AND MARKET RESEARCH AAKP's role in Clinical Trials and Market Research AAKP supports innovation in the kidney space. We are actively involved in market research - to share the patient voice
More informationMini Summit 24: Evolving Risks and Opportunities related to Medical Affairs, e.g. Professional Medical Education, Digital Information, etc.
November 8, 2018, 2:45 p.m. Mini Summit 24: Evolving Risks and Opportunities related to Medical Affairs, e.g. Professional Medical Education, Digital Information, etc. 1 Panel Introductions BJ D Avella,
More informationPatient Handbook on Stem Cell Therapies
Patient Handbook on Stem Cell Therapies WWW.ISSCR.ORG WWW.CLOSERLOOKATSTEMCELLS.ORG Patient Handbook on Stem Cell Therapies Introduction We have all heard about the extraordinary promise that stem cell
More informationInternational Myeloma Foundation Myeloma Action Month Proclamation Kit
International Myeloma Foundation Myeloma Action Month Proclamation Kit A How-To-Guide for Proclamations 2 Finding Your Champion 3 Sample Cover Letter to Legislator 4 Sample Proclamation.. 5-6 Sample Press
More informationNew Paradigms in Drug Discovery: How Genomic Data are Being Used to Revolutionize the Drug Discovery and Development Process A Workshop
Board on Health Sciences Policy Roundtable on Translating Genomic-Based Research for Health New Paradigms in Drug Discovery: How Genomic Data are Being Used to Revolutionize the Drug Discovery and Development
More informationEmployment in the biopharma industry grew almost 5 percent in 2014, the last full year for which we have data. This is the highest annual growth rate
Thank you, Mr. Chairman, and members of the committee. I m Sarah MacDonald, Executive Vice President at MassBio, the life sciences trade association now representing over 700 member organizations. First,
More informationA LOOK AT WHAT S INSIDE
ADVOCACY TOOLKIT A LOOK AT WHAT S INSIDE WELCOME... 3 RESOURCES FOR YOU... 4 Why Get Involved?... 5 Key Messages... 6 Ways to Engage... 7 RESOURCES FOR YOUR MEMBERS... 8 Fact Sheet: Did You Know?... 9
More informationStatements on the Regulation of Laboratory Developed Tests
Statements on the Regulation of Laboratory Developed Tests Current Regulatory Gaps and Perspectives on Oversight of LDTs American Cancer Society Cancer Action Network says Molecular tests, in particular,
More informationPolicy Principles for a Robust Biotechnology Sector
2013/SOM1/LSIF/004a Agenda Item: 6b Policy Principles for a Robust Biotechnology Sector Purpose: Information Submitted by: Biotechnology Industry Organization Life Sciences and Innovative Forum Planning
More informationJonathan Davis, MD Vice-Chair of Pediatrics, Floating Hospital for Children at Tufts Medical Center, Boston, MA Chair, Neonatal Advisory Committee,
Jonathan Davis, MD Vice-Chair of Pediatrics, Floating Hospital for Children at Tufts Medical Center, Boston, MA Chair, Neonatal Advisory Committee, Office of the Commissioner, FDA 2 Informed Consent Consent
More informationBipartisan Policy Center, Top Medical Innovation Priorities
Bipartisan Policy Center, Top Medical Priorities FDA: Advancing Medical is a Bipartisan Policy Center initiative led by former Senator Bill Frist, MD, former Congressman Bart Gordon, and BPC Health Initiative
More informationStreamlining IRB Procedures for Expanded Access
Streamlining IRB Procedures for Expanded Access Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation Richard Klein Director, FDA Patient Liaison Program Office of Health and Constituent Affairs
More informationNational Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy
From Hope to Cures: The Value of Biopharmaceutical Innovation National Foundation for Women Legislators Annual Meeting September 12, 2015 Tara Ryan Vice President, State Government Advocacy HIV/AIDS: Then
More informationTestimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association
Testimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association Before the House Energy and Commerce Subcommittee on Health 21st Century Cures: Examining the Regulation of Laboratory
More informationRole of the FDA and PDUFA in Drug Development
Role of the FDA and PDUFA in Drug Development Questions to be addressed 1. What is the Food and Drug Administration and why is it important? 2. Why was the Prescription Drug User Fee Act (PDUFA) created?
More informationRegulatory Innovations in Neurological Disorder Therapies, including Spinraza and Exondys 51
Regulatory Innovations in Neurological Disorder Therapies, including Spinraza and Exondys 51 ASENT 19 th Annual Meeting March 15, 2017 Frank Sasinowski, M.S., M.P.H., J.D Director, Hyman, Phelps & McNamara,
More informationRARE DISEASE DAY CONFERENCE 2018: Building on Research Excellence to Improve Patient Care Two-Day Interactive Conference
March 21-22, 2018 DELTA OTTAWA CITY CENTRE, 101 Lyon Street Ottawa, Ontario How this Conference Will Make a Difference (for Rare Diseases in Canada) Day 1 (AM) In May 2015, the Canadian Organization for
More informationPresentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development
Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development 23 November 2009 Sharon F. Terry, MA President & CEO, Genetic Alliance Executive Director, PXE International
More information7/20/2016. Disclaimer
Disclaimer Organizations may not re-use material presented at this AMCP webinar for commercial purposes without the written consent of the presenter, the person or organization holding copyright to the
More informationRegulatory Overview of Proposed LDT Framework. FDA Concerns. Background. FDA Proposed Regulatory Approach. By Ben Berg, Meaghan Bailey, RAC
Regulatory Overview of Proposed LDT Framework By Ben Berg, Meaghan Bailey, RAC On July 31, 2014, the U.S. Food and Drug Administration (FDA or the Agency) notified both the Senate Committee on Health,
More informationConsortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts
Consortia-Based Strategies in Neurodegenerative Diseases: Critical Path Institute s Track Record in Collaborative Efforts Martha A. Brumfield, PhD President & CEO Agenda C-Path Model for Collaboration
More information21 st Century Cures Act: Progress Update
21 st Century Cures Act: Progress Update ShaAvhrée Buckman-Garner, MD, PhD Director, Office of Translational Sciences Center for Drug Evaluation and Research September 25, 2017 Background 21 st Century
More informationPDUFA VI Public Meeting Remarks of Cynthia A. Bens Alliance for Aging Research. August 15, 2016
1 PDUFA VI Public Meeting Remarks of Cynthia A. Bens Alliance for Aging Research August 15, 2016 Panel 1: Pre-Market Review and Post-Market Safety Good morning everyone and thanks to the FDA for inviting
More informationDocket #: FDA-2018-D-3268
Subject: Comment on FDA Draft Guidance for Industry Titled Rare Diseases: Early Drug Development and the Role of Pre-Investigational New Drug Application Meetings Docket #: FDA-2018-D-3268 ARM is an international
More informationThe adult cancer pipeline has almost 900 drugs in it. The pediatric cancer pipeline? It s so small that few of us know much about it.
Prepared Comments to BDA workshop: Improving oncology drug development for children and adolescents" (Paris, 18 & 19 November 2013) Nancy Goodman Executive Director Kids v Cancer Thank you all for inviting
More information@ALSETF #EAP2015. Jess B. Rabourn CBI Expanded Access Conference July 22, 2015
How to Win Physician Collaboration Models for Advancing Access to Lifesaving Therapies @ALSETF #EAP2015 Jess B. Rabourn CBI Expanded Access Conference July 22, 2015 How to Win Now that we want Expanded
More informationSTRIKING A BALANCE ADMINISTRATIVE COST-SHARING IN SCHOOL HEALTH CENTERS. Thursday, June 15, 2006
STRIKING A BALANCE ADMINISTRATIVE COST-SHARING IN SCHOOL HEALTH CENTERS Blair Harvey, Project Director, Illinois Coalition for School Health Centers Amy Valukas, Director, School Based Health, Erie Family
More informationmedicines, improving the health of people around the world.
TransCelerate BioPharma Inc. is a non-profit organization with a mission to collaborate across the biopharmaceutical research and development community to identify, design and facilitate the implementation
More informationInvesting in Rare Disease Patient Advocacy Groups
Investing in Rare Disease Patient Advocacy Groups Written by: Pooja Doshi, Engagement Manager, ClearView Healthcare Partners Chris Von Seggern, Partner, ClearView Healthcare Partners Patient Advocacy Groups
More informationBrain Tumour Australia Information FACT SHEET 22 Clinical Trials: Questions and Answers
FACT SHEET 22 Clinical Trials: Questions and Answers What is a clinical trial? Clinical trials are research studies that answer scientific questions and try to find better ways to prevent, screen for,
More informationExecutive Search. Executive Officer
Executive Search Executive Officer Client Overview The American Society for Investigative Pathology (ASIP) has retained Sterling Martin Associates to search for its next Executive Officer. The position
More informationFast track Approval process- Ethical considerations
Fast track Approval process- Ethical considerations Sara Ingersoll, MS Program Assistant, Health Sciences Institutional Review Board Rutgers, The State University of New Jersey New Brunswick/Piscataway
More informationAmarex Clinical Research Washington DC metro area A Product Development Services Company. From Lab to Market Approval
Amarex Clinical Research Washington DC metro area A Product Development Services Company Regulatory Strategy From Lab to Market Approval Strategy Implementation Pre-Clinical Assays Global Clinical Trials
More informationFDA Guidance, Clinical Pharmacology, and Regulatory Science
Principles of Clinical Pharmacology NIH, April 25, 2013 FDA Guidance, Clinical Pharmacology, and Regulatory Science Carl Peck, MD UCSF Center for Drug Development Science Washington DC and San Francisco
More informationCLINICAL TRIALS: WHAT YOU NEED TO KNOW
CLINICAL TRIALS: WHAT YOU NEED TO KNOW www.kidney.org National Kidney Foundation's Kidney Disease Outcomes Quality Initiative Did you know that the National Kidney Foundation's Kidney Disease Outcomes
More informationUnrealized Savings from the Misuse of REMS and Non-REMS Barriers. By Alex Brill
Unrealized Savings from the Misuse of REMS and Non-REMS Barriers By Alex Brill September 2018 EXECUTIVE SUMMARY Risk Evaluation and Mitigation Strategies (REMS) are drug safety programs required by the
More informationAN INSIGHT ON ORPHAN DRUG DEVELOPMENT STRATEGY IN US AND EUROPE
ISSN: 2230-7346 Dilip Maheshwari, et al. / JGTPS / 6(1)-(2015) 2322 2327 (Review Article) Journal of Global Trends in Pharmaceutical Sciences Journal home page: www.jgtps.com AN INSIGHT ON ORPHAN DRUG
More informationNETWORKING AND CUREACCELERATOR LIVE!
RARE DRUG DEVELOPMENT SYMPOSIUM A PARTNERSHIP BETWEEN PENN MEDICINE ORPHAN DISEASE CENTER AND GLOBAL GENES PHILADELPHIA, PENNSYLVANIA NETWORKING AND CUREACCELERATOR LIVE! CureAccelerator Live! Rare Disease
More informationAccess to Unapproved Drugs: Expanded Access and Right to Try
Access to Unapproved Drugs: Expanded Access and Right to Try Alison Bateman-House, PhD, MPH, MA Assistant Professor, Division of Medical Ethics Co-Chair, Working Group on Compassionate Use and PreApproval
More informationRare Diseases: Challenges and Opportunities NIH Perspective
Rare Diseases: Challenges and Opportunities NIH Perspective Stephen C. Groft, Pharm.D. Office of Rare Diseases Research (ORDR) National Center for Advancing Translational Science (NCATS) National Institutes
More informationPFF DISEASE EDUCATION WEBINAR SERIES. Welcome!
PFF DISEASE EDUCATION WEBINAR SERIES Welcome! PFF DISEASE EDUCATION WEBINAR SERIES David J. Lederer, MD, MS PFF Senior Medical Advisor, Patient Communications Harold Collard, MD PFF Medical Advisory Board
More informationRegulatory Perspectives on Gene Therapies for Rare Diseases Rare Diseases Forum Washington, D.C. October 17, 2018
Regulatory Perspectives on Gene Therapies for Rare Diseases Rare Diseases Forum Washington, D.C. October 17, 2018 Rachel Witten, M.D. Medical Officer Office of Tissues and Advanced Therapies Center for
More informationPharmacovigilance and Drug Safety Compliance Update GAP Analysis: How We Get to Where We Want to Be
Pharmacovigilance and Drug Safety Compliance Update GAP Analysis: How We Get to Where We Want to Be John P. Ford Sidley Austin LLP Core PV Concepts Risk identification, collection of information Risk assessment,
More informationMeasuring Chemicals in People What Would You Say? A Boston Consensus Conference on Biomonitoring. December 11, 2006
Measuring Chemicals in People What Would You Say? A Boston Consensus Conference on Biomonitoring Consensus Statement December 11, 2006 Government by the people and for the people. We represent the general
More informationCTTI Overview One Decade of Impact. One Vision Ahead.
Feb. 6, 2018 CTTI Overview One Decade of Impact. One Vision Ahead. Pamela Tenaerts, MD, MBA Executive Director #CelebrateCTTI Discover how CTTI has influenced the clinical trials enterprise during the
More informationIndustry Case Study: Expanded Access at Ultragenyx
Industry Case Study: Expanded Access at Ultragenyx Hank Mansbach, MD VP, Medical Affairs September 13, 2016 www.ultragenyx.com Introduction to Ultragenyx A clinical-stage biopharmaceutical company based
More informationRare Diseases and CDER: Challenges and Opportunities
Rare Diseases and CDER: Challenges and Opportunities The Science of Small Clinical Trials November 27 & 28, 2012 Kathryn O Connell, MD PhD Medical Officer, Rare Diseases Program Office of New Drugs, CDER,
More informationTop 10. Changing Enforcement Environment. The Fourth Annual Medical Device Regulatory, Reimbursement and Compliance Congress November 10, 2009
The Fourth Annual Medical Device Regulatory, Reimbursement and Compliance Congress November 10, 2009 Roundtable on the Top 10 Device Manufacturer-FDA Regulatory Issues Dorothy J. Clarke, Esq., Vice President,
More informationAcquisition of Vtesse Inc. Increased Focus on Orphan and Pediatric Diseases
Acquisition of Vtesse Inc. Increased Focus on Orphan and Pediatric Diseases 1 Forward Looking Statement This presentation contains "forward-looking statements" as that term is defined in the Private Securities
More informationStrategic Plan. Uniting to care & cure
2017-2019 Strategic Plan Uniting to care & cure Table of Contents Message from the President & CEO Page 2 Overview Page 3 Mission Page 4 Core Values Page 5 2017-2019 Objectives & Strategies Page 6 Mission
More informationRe: Docket No. FDA-2018-D-1895: Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products Content and Format
September 7, 2018 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2018-D-1895: Indications and Usage Section of Labeling
More informationPediatric Drug Development:
Pediatric Drug Development: Where Have We Been and Where Are We Going? Barry Mangum, PharmD, FCP Director Clinical Pharmacology Duke Clinical Research Center Duke University Medical Center Specialty Pediatric
More informationA LEADER IN SPECIALTY CARE
A LEADER IN SPECIALTY CARE Zi Qing, Pompe Disease, Taiwan SCIENCE-DRIVEN, PATIENT-FOCUSED Patients and science are at the center of everything we do, defining and uniting our efforts across rare diseases,
More informationsocial, and population-based research conducted and supported by the National Institutes of Health (NIH). The
Statement by the Ad Hoc Group for Medical Research on FY 2015 Appropriations for the National Institutes of Health Submitted for the record on March 28, 2014, to the Subcommittee on Labor, Health and Human
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited. Special Review Designations & Approval Pathways Special Designations
More information